Manufacturer VerifiedUnited States

Boston Scientific Corporation

Boston Scientific

Boston Scientific Corporation is a global leader in medical technology that transforms lives through innovative interventional medical solutions, founded in 1979 in Marlborough, Massachusetts, United States. Built on a category leadership strategy across seven core businesses, the company designs and manufactures a comprehensive portfolio of minimally invasive cardiovascular, endoscopy, urology, and neuromodulation devices, encompassing drug-eluting coronary stents and balloon catheters, transcatheter aortic valve replacement (TAVR) systems including the ACURATE neo2 platform, the WATCHMAN left atrial appendage closure device, peripheral atherectomy and thrombectomy systems, cardiac rhythm management devices including pacemakers and ICDs, GI endoscopy tools for hemostasis and tissue resection, kidney stone laser lithotripsy systems, sacral neuromodulation for bladder and bowel control, and spinal cord stimulation for chronic pain management. With annual revenue of US$20.074 billion in 2025, Boston Scientific operates 25+ manufacturing and distribution facilities globally, employing approximately 59,000 employees across 130+ countries. The company has delivered one of the strongest organic growth trajectories in large-cap medtech, consistently outperforming peers with double-digit annual revenue growth since 2022.

Strengths: Best-in-class organic growth among large-cap medical device companies, driven by category leadership in high-growth markets like structural heart, electrophysiology, and interventional oncology. WATCHMAN franchise dominance with virtually uncontested market position in left atrial appendage closure and expanding indications. FARAPULSE pulsed field ablation system establishing early leadership in the next-generation atrial fibrillation treatment paradigm. Strategic M&A discipline with Bolt Medical, Axonics, and Silk Road Medical acquisitions expanding total addressable market into new interventional categories. Strong emerging market penetration with double-digit growth across Asia-Pacific and Latin America.
Weaknesses: Heart valve competition from Edwards Lifesciences and Medtronic in the TAVR market, where Boston Scientific holds a smaller share. Integration complexity from multiple simultaneous large acquisitions that could strain operational execution and culture. Cardiac rhythm management segment facing secular headwinds from declining pacemaker volumes in developed markets.

Business Nature

Boston Scientific Corporation is a global developer, manufacturer, and marketer of minimally invasive medical devices used in interventional medical specialties. The company operates a diversified manufacturing network with 25+ facilities and distribution centers worldwide, producing Class II and Class III medical devices including coronary stents, cardiac rhythm management devices, structural heart implants, and endoscopy tools. Boston Scientific's business model centers on a category leadership strategy, targeting high-growth interventional markets where it can achieve a number one or number two position through organic innovation and strategic acquisitions. The company generates revenue through both capital equipment placements e.g., POLARx cryoablation, FARAPULSE PFA and recurring disposable device sales stents, catheters, leads, creating a balanced mix of one-time and recurring revenue streams.

Core Business Areas

Interventional Cardiology – Coronary & Structural Heart • SYNERGY drug-eluting stents with bioabsorbable polymer coating • AGENT drug-coated balloon for coronary in-stent restenosis • WATCHMAN FLX and WATCHMAN FLX Pro left atrial appendage closure devices • ACURATE neo2 transcatheter aortic valve implantation TAVI system • SENTINEL cerebral embolic protection system for TAVR procedures Cardiac Rhythm Management & Electrophysiology – Arrhythmia Management • FARAPULSE pulsed field ablation system for atrial fibrillation • POLARx cryoablation system for pulmonary vein isolation • INGENIO, DYNAGEN, and COGNIS pacemakers and ICDs • RHYTHMIA HDx 3D mapping system for complex arrhythmia navigation • EMBLEM subcutaneous implantable defibrillator S-ICD Peripheral Interventions – Vascular & Oncology • ELUVIA drug-eluting peripheral stent for femoropopliteal disease • RANGER drug-coated balloon for peripheral artery disease • ANGIOLET and EKOS thrombolytic and thrombectomy systems • TheraSphere Y-90 radioembolization for liver cancer • INTERLOCK and RUBY coil embolization systems Endoscopy – Gastrointestinal & Pulmonary • SpyGlass DS direct visualization system for cholangioscopy • AXIOS lumen-apposing metal stent for endoscopic drainage • Resolution clips and ORISE tissue resection devices • EXALT single-use bronchoscope and duodenoscope Urology and Pelvic Health – Stone & Prostate Management • Lumenis MOSES laser lithotripsy for kidney stone treatment • Rezum water vapor therapy for benign prostatic hyperplasia • Axonics sacral neuromodulation for overactive bladder and fecal incontinence • AMS 800 artificial urinary sphincter

Industry Rankings

7Top 10 Advanced Medical Equipment Companies

Brand

7Top 10 Advanced Medical Equipment Manufacturers & Suppliers

Mfr

Corporate Report

Boston Scientific Corporation is a global medical technology leader headquartered in Marlborough, Massachusetts. Founded in 1979 by John Abele and Peter Nicholas, the company has grown into one of the world's largest medical device manufacturers with US$20.074 billion in 2025 revenue, approximately 59,000 employees, and a presence in 130+ countries.

Core Business

Boston Scientific operates across seven core interventional medical specialties: Interventional Cardiology, Structural Heart, Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, and Urology/Pelvic Health. The company's category leadership strategy has produced category-defining products including the WATCHMAN FLX left atrial appendage closure device (dominant market share), the FARAPULSE pulsed field ablation system (early leadership in next-gen AFib therapy), the AGENT drug-coated balloon (first FDA-approved coronary DCB), and the SpyGlass DS cholangioscopy platform. The company generates approximately 85% of revenue from single-use devices and implants, creating a highly recurring revenue model.

Global Presence

The company operates 25+ manufacturing and distribution facilities across the United States, Ireland, Costa Rica, Malaysia, and other key locations. With approximately 59,000 employees globally, Boston Scientific serves customers in 130+ countries, with the United States representing approximately 58% of revenue and international markets contributing 42%. The company has been investing aggressively in emerging markets with double-digit growth in Asia-Pacific (particularly China and India) and expanding its manufacturing footprint in Penang, Malaysia and other cost-advantaged locations.

Key Strengths

Boston Scientific has established itself as the fastest-growing large-cap medical device company, consistently delivering double-digit organic revenue growth since 2022 — outpacing peers by a wide margin. The WATCHMAN franchise enjoys near-monopoly positioning in left atrial appendage closure with limited direct competition. The FARAPULSE system represents early market leadership in the pulsed field ablation segment, a major paradigm shift in atrial fibrillation treatment. The company's strategic acquisition program (Axonics, Silk Road Medical, Bolt Medical) has systematically expanded its total addressable market into adjacent interventional categories.

VerityRank Score

VerityRank Score of 89/100

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Marlborough, Massachusetts, United States

Founded

1979

Employees

59,000

Factories

25+ manufacturing and distribution facilities worldwide

Listing

NYSE: BSX

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website NYSE: BSX , Data Sources & Methodology

Boston Scientific Official Website
Boston Scientific - Wikipedia
Boston Scientific Investor Relations
Boston Scientific Revenue - Macrotrends
Boston Scientific 2025 Annual Report

Back to Rankings